Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure

Steve S. Lee, Matthew J. Price, Garrett B Wong, Rafael Valencia, Samir Damani, Neil Sawhney, Raghava R. Gollapudi, Richard A. Schatz, Paul S. Teirstein

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The optimal treatment for sirolimus-eluting stent (SES) restenosis is not known. This study evaluated the safety and clinical outcome of paclitaxel-eluting stent (PES) implantation for SES restenosis. From March 2004 to July 2005, PESs were implanted in 125 patients with 140 lesions with SES restenosis. Acute and 6-month clinical outcomes were determined through review of the medical record and/or telephone interview. In-hospital major adverse cardiac events (death, nonfatal myocardial infarction, or repeat revascularization) occurred in 14 patients (11.2%), driven entirely by postprocedure non-Q-wave myocardial infarction. At a mean clinical follow-up of 7.2 ± 1.8 months, the incidence of target lesion revascularization (TLR) was 14.0%, and the rate of major adverse cardiac events was 17.2%. Subacute thrombosis occurred in 2 patients (1.6%). Length of PES implanted, postprocedure diameter stenosis, and total occlusion of the target lesion were independent predictors of TLR. In patients with de novo SES restenosis, TLR was only 8.7%. In conclusion, at medium-term follow-up, PES implantation for SES failure appears to be safe and effective, although efficacy is decreased in the setting of total occlusions, greater residual diameter stenosis, and longer PESs.

Original languageEnglish (US)
Pages (from-to)1345-1348
Number of pages4
JournalAmerican Journal of Cardiology
Volume98
Issue number10
DOIs
StatePublished - Nov 15 2006
Externally publishedYes

Fingerprint

Sirolimus
Paclitaxel
Stents
Pathologic Constriction
Myocardial Infarction
Medical Records
Thrombosis
Interviews
Safety
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure. / Lee, Steve S.; Price, Matthew J.; Wong, Garrett B; Valencia, Rafael; Damani, Samir; Sawhney, Neil; Gollapudi, Raghava R.; Schatz, Richard A.; Teirstein, Paul S.

In: American Journal of Cardiology, Vol. 98, No. 10, 15.11.2006, p. 1345-1348.

Research output: Contribution to journalArticle

Lee, SS, Price, MJ, Wong, GB, Valencia, R, Damani, S, Sawhney, N, Gollapudi, RR, Schatz, RA & Teirstein, PS 2006, 'Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure', American Journal of Cardiology, vol. 98, no. 10, pp. 1345-1348. https://doi.org/10.1016/j.amjcard.2006.07.023
Lee, Steve S. ; Price, Matthew J. ; Wong, Garrett B ; Valencia, Rafael ; Damani, Samir ; Sawhney, Neil ; Gollapudi, Raghava R. ; Schatz, Richard A. ; Teirstein, Paul S. / Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 10. pp. 1345-1348.
@article{a0a4774a92a44efda135d38a6f3f91f8,
title = "Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure",
abstract = "The optimal treatment for sirolimus-eluting stent (SES) restenosis is not known. This study evaluated the safety and clinical outcome of paclitaxel-eluting stent (PES) implantation for SES restenosis. From March 2004 to July 2005, PESs were implanted in 125 patients with 140 lesions with SES restenosis. Acute and 6-month clinical outcomes were determined through review of the medical record and/or telephone interview. In-hospital major adverse cardiac events (death, nonfatal myocardial infarction, or repeat revascularization) occurred in 14 patients (11.2{\%}), driven entirely by postprocedure non-Q-wave myocardial infarction. At a mean clinical follow-up of 7.2 ± 1.8 months, the incidence of target lesion revascularization (TLR) was 14.0{\%}, and the rate of major adverse cardiac events was 17.2{\%}. Subacute thrombosis occurred in 2 patients (1.6{\%}). Length of PES implanted, postprocedure diameter stenosis, and total occlusion of the target lesion were independent predictors of TLR. In patients with de novo SES restenosis, TLR was only 8.7{\%}. In conclusion, at medium-term follow-up, PES implantation for SES failure appears to be safe and effective, although efficacy is decreased in the setting of total occlusions, greater residual diameter stenosis, and longer PESs.",
author = "Lee, {Steve S.} and Price, {Matthew J.} and Wong, {Garrett B} and Rafael Valencia and Samir Damani and Neil Sawhney and Gollapudi, {Raghava R.} and Schatz, {Richard A.} and Teirstein, {Paul S.}",
year = "2006",
month = "11",
day = "15",
doi = "10.1016/j.amjcard.2006.07.023",
language = "English (US)",
volume = "98",
pages = "1345--1348",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure

AU - Lee, Steve S.

AU - Price, Matthew J.

AU - Wong, Garrett B

AU - Valencia, Rafael

AU - Damani, Samir

AU - Sawhney, Neil

AU - Gollapudi, Raghava R.

AU - Schatz, Richard A.

AU - Teirstein, Paul S.

PY - 2006/11/15

Y1 - 2006/11/15

N2 - The optimal treatment for sirolimus-eluting stent (SES) restenosis is not known. This study evaluated the safety and clinical outcome of paclitaxel-eluting stent (PES) implantation for SES restenosis. From March 2004 to July 2005, PESs were implanted in 125 patients with 140 lesions with SES restenosis. Acute and 6-month clinical outcomes were determined through review of the medical record and/or telephone interview. In-hospital major adverse cardiac events (death, nonfatal myocardial infarction, or repeat revascularization) occurred in 14 patients (11.2%), driven entirely by postprocedure non-Q-wave myocardial infarction. At a mean clinical follow-up of 7.2 ± 1.8 months, the incidence of target lesion revascularization (TLR) was 14.0%, and the rate of major adverse cardiac events was 17.2%. Subacute thrombosis occurred in 2 patients (1.6%). Length of PES implanted, postprocedure diameter stenosis, and total occlusion of the target lesion were independent predictors of TLR. In patients with de novo SES restenosis, TLR was only 8.7%. In conclusion, at medium-term follow-up, PES implantation for SES failure appears to be safe and effective, although efficacy is decreased in the setting of total occlusions, greater residual diameter stenosis, and longer PESs.

AB - The optimal treatment for sirolimus-eluting stent (SES) restenosis is not known. This study evaluated the safety and clinical outcome of paclitaxel-eluting stent (PES) implantation for SES restenosis. From March 2004 to July 2005, PESs were implanted in 125 patients with 140 lesions with SES restenosis. Acute and 6-month clinical outcomes were determined through review of the medical record and/or telephone interview. In-hospital major adverse cardiac events (death, nonfatal myocardial infarction, or repeat revascularization) occurred in 14 patients (11.2%), driven entirely by postprocedure non-Q-wave myocardial infarction. At a mean clinical follow-up of 7.2 ± 1.8 months, the incidence of target lesion revascularization (TLR) was 14.0%, and the rate of major adverse cardiac events was 17.2%. Subacute thrombosis occurred in 2 patients (1.6%). Length of PES implanted, postprocedure diameter stenosis, and total occlusion of the target lesion were independent predictors of TLR. In patients with de novo SES restenosis, TLR was only 8.7%. In conclusion, at medium-term follow-up, PES implantation for SES failure appears to be safe and effective, although efficacy is decreased in the setting of total occlusions, greater residual diameter stenosis, and longer PESs.

UR - http://www.scopus.com/inward/record.url?scp=33750506306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750506306&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.07.023

DO - 10.1016/j.amjcard.2006.07.023

M3 - Article

C2 - 17134626

AN - SCOPUS:33750506306

VL - 98

SP - 1345

EP - 1348

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 10

ER -